Oasil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oasil

Quick Facts about Oasil

Property Description
Active ingredient Chlordiazepoxide
Form Oral Capsule, Injectable Solution
Pharmacological class Benzodiazepine / Anxiolytic
General purpose Reducing severe anxiety and agitation
Origin Synthetic

Defining Oasil and Its Classification

Oasil is a trade name for a medication whose active component is the synthetic compound Chlordiazepoxide, which is classified as an anxiolytic belonging to the benzodiazepine pharmacological class. This compound is categorized as a Central Nervous System (CNS) depressant because its fundamental action is to slow down excessive neuronal activity. Chlordiazepoxide holds historical significance as the prototype benzodiazepine, being the first compound in this critical drug class to be synthesized and approved for medical application. Its potent activity necessitates that it is strictly a prescription-only substance, with its classification clinically recognized for providing effective short-term relief in states of acute agitation.


Composition and Physical Form of Oasil

Oasil is a single-ingredient product whose primary therapeutic effect is derived entirely from the active substance, Chlordiazepoxide, and its subsequent active metabolites. The drug is typically supplied in one of two main physical forms: the oral capsule for standard therapy, and, less commonly, as an injectable solution for use in acute clinical settings. The availability of both forms dictates the general route of administration (oral or injection), allowing healthcare providers flexibility. Chlordiazepoxide forms pharmacologically active metabolites such as desmethyldiazepam, which extend its therapeutic duration.


General Therapeutic Purpose of Oasil

The general therapeutic purpose of Oasil is to promote a state of relative calmness and relaxation by acting as a "brake" on overactive nerve signals in the brain. As an anxiolytic and minor tranquilizer, its core function is to reduce emotional and physical tension, helping to settle states of severe unease, generalized agitation, and restlessness. The drug is generally recommended for its ability to reduce symptoms related to anxiety and acute distress, alleviating hyper-arousal and tension in the central nervous system to ease acute psychological distress and associated physical symptoms like muscle tightness.

Regulatory References

  1. Chlordiazepoxide - StatPearls - NCBI Bookshelf

What side effects are possible with Oasil?

Possible Side Effects and Safety Information

Oasil (chlordiazepoxide) is classified as a Central Nervous System (CNS) depressant. The drug's safety profile, as documented in government regulatory sources, defines potential risks based on frequency, systemic impact, and duration of exposure.

Documented Adverse Reactions

The most frequently encountered adverse reactions are extensions of the drug's CNS activity and often occur at the start of therapy or with higher doses. Safety classifications may vary by region, but the following effects are commonly documented:

System-Organ Class Common Adverse Reactions
Nervous System Drowsiness, Ataxia (lack of coordination), Confusion, Slurred Speech
Psychiatric Paradoxical reactions (e.g., excitement, stimulation, acute rage)
Other Systemic Skin eruptions, Edema (swelling), Minor menstrual irregularities

Serious Safety Considerations

The official labeling notes that Oasil may carry risks for serious, though rare, adverse reactions that require clinical monitoring. These include severe systemic effects and high-risk scenarios:

  • Hematological Events: Potential for blood dyscrasias, including agranulocytosis.
  • Hepatobiliary Disorders: Risk of jaundice and serious liver dysfunction.
  • Respiratory Risk: Danger of profound sedation and respiratory depression, especially when used concurrently with opioids or other CNS depressants, which has been highlighted by the FDA.

Population-Specific and Time-Related Warnings

Safety data specifies caution for certain groups. Older adults and debilitated patients, along with individuals having impaired hepatic or renal function, are noted to be more susceptible to CNS adverse effects, necessitating careful observation.

Furthermore, use of Oasil is associated with time-dependent safety patterns. While initial side effects are common, there is a documented risk of physical and psychological dependence with long-term use, and abrupt cessation can lead to acute withdrawal syndrome. The drug is contraindicated in conditions such as known hypersensitivity to benzodiazepines, severe respiratory insufficiency, and severe hepatic insufficiency.

Overdose and Emergency Response

Official Overdose Manifestations

Overdose of Oasil (chlordiazepoxide) primarily results in excessive depression of the Central Nervous System (CNS). The documented signs and symptoms, according to regulatory information, include:

  • CNS Effects: Drowsiness, mental confusion, stupor, and ultimately coma.
  • Coordination/Motor: Impaired reflexes, loss of coordination (ataxia), and muscle weakness.
  • Systemic: Low blood pressure (hypotension), shallow or slowed breathing (respiratory depression), and low body temperature.

Life-Threatening Outcomes

Regulatory warnings note the risk of profound sedation, severe respiratory depression, coma, and death in overdose, particularly when Oasil is combined with other CNS depressants, such as alcohol or opioids.

Overdose effects are also noted to be more likely and severe in elderly or debilitated patients, who are generally more sensitive to the drug's effects.

When Immediate Medical Help Is Required

Official government guidance mandates seeking immediate medical attention right away if overdose is suspected. Specifically, emergency medical help must be sought if signs of severe toxicity occur, such as:

  • Shallow or slowed breathing (respiratory depression).
  • Breathing stops.
  • Extreme sleepiness or unresponsiveness.

Management is defined as symptomatic and supportive treatment, requiring the monitoring of vital signs (respiration, pulse, and blood pressure) and maintenance of an adequate airway.

Therapeutic Uses of Oasil

What Oasil Treats: Main Uses and Benefits

Oasil (chlordiazepoxide) is commonly used to help with symptoms related to heightened physiological activity and severe emotional tension, particularly in acute clinical contexts.

Its primary therapeutic role is in managing anxiety disorders, addressing symptoms of acute alcohol withdrawal, and providing support for pre-operative apprehension. It is applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms.

The medication is relevant for easing challenging symptoms like pronounced nervousness, restlessness, and acute agitation. In the context of substance withdrawal, it is used for managing symptoms associated with temporary physiological imbalance such as severe tremor and physical hyper-arousal. The supportive relief may assist with maintaining functional stability during symptom fluctuations.

“Oasil is applied in scenarios where additional management of discomfort is required, and the medication may help ease the overall symptom burden.”

Quick Fact: Relief for Acute Tension

Focus Symptom Category Patient Benefit
Primary Use Acute Agitation & Anxiety Contributes to improved day-to-day comfort during periods of heightened symptoms.
Specialized Use Alcohol Withdrawal Tremor Assists with maintaining functional stability.
Clinical Scenario Pre-Procedure Anxiety Is relevant for easing temporary distress.

Regulatory References

  1. NIH DailyMed drug label information

Eligibility and Restrictions for Use

This information is strictly based on official regulatory documents concerning population eligibility for Oasil (Clopidogrel-like active substance).

Populations Excluded from Use

Classification Excluded Groups/Conditions
Contraindicated (Absolute Prohibition) Patients with Active Pathological Bleeding (e.g., peptic ulcer or intracranial hemorrhage); those with Severe Hepatic Impairment; or individuals with known Hypersensitivity to the active substance or excipients.
Not Recommended (Lack of Established Data) Pediatric population (children and adolescents).

Use in Specific Populations

Population Category Regulatory Status
Adults Primarily authorized for use in the adult population.
Pregnancy Not recommended. Safety and efficacy for the developing fetus have not been conclusively established in humans.
Lactation/Breastfeeding Not recommended. It is unknown if the substance is excreted into human milk.
Organ Impairment Use requires caution in patients with pre-existing Renal Impairment and Moderate Hepatic Impairment due to limited clinical experience.

Official regulatory guidelines state that patients with conditions that increase the risk of bleeding, such as a recent ischaemic stroke (within seven days), must be managed with caution. This framework defines that the medicine is reserved for adults who are free of severe bleeding risks and key organ failures.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Oasil (chlordiazepoxide) is defined by its potential for pharmacodynamic interactions and documented effects on drug clearance. The co-administration of Oasil with Opioid Analgesics may result in profound sedation, respiratory depression, coma, and death due to an additive Central Nervous System (CNS) depressant effect, a combination that regulatory agencies mandate be reserved for use only when alternative treatments are inadequate. Similarly, co-administration with Alcohol (Ethanol) should be avoided as it enhances the sedative and central depressive effects.

Pharmacokinetic and Substance Restrictions

Classification Interacting Entity Official Outcome/Restriction
Avoided Combination Sodium Oxybate Enhanced effects; use should be avoided due to increased respiratory depression.
Clearance Reduction Hepatic Enzyme Inhibitors (e.g., Cimetidine, Oral Contraceptive Agents) Clearance is reduced, which may potentiate its action (increase exposure).
Effect Reduction Theophylline The effects of Oasil are possibly reduced.
Population Note Impaired Hepatic Function Risk of slower removal from the body and increased subsequent effects.

Co-administration with other centrally-acting drugs (such as hypnotics and neuroleptics) is likely to intensify the central depressive effects. Prescribing information requires strict adherence to limitations regarding the concomitant use of Oasil with substances that amplify CNS depression.

Mechanism of Action

Enhancement of Central Inhibitory Signaling

Oasil ( Chlordiazepoxide) functions as a Positive Allosteric Modulator ( PAM) of the GABA A receptor complex, the main inhibitory target in the CNS. By binding to an allosteric site, the drug enhances the function of GABA, leading to a higher frequency of chloride ion influx ( Cl^-) and hyperpolarization of the nerve cell membrane. This molecular action decreases the neuron's resistance to excitatory signals in CNS circuits, including those modulating arousal.


The Mechanistic Cascade to Systemic Inhibition

The resulting neuronal hyperpolarization modulates activity within the Limbic System and key motor pathways in the brainstem and spinal cord. This inhibitory action alters signal transmission, functionally generating modulation of muscle tone via effects on spinal cord interneurons. The drug is also metabolized into pharmacologically active metabolites that share the same GABA A receptor modulation, providing a prolonged functional consequence of the pathway's inhibition. The mechanism is dependent on the presence of the endogenous GABA and is subject to diminished mechanistic effect due to receptor changes with sustained GABA A receptor activation.

Dosage and Administration Information

How Oasil is Used

Oasil (chlordiazepoxide) usage is governed by its administration methods and defined dose ranges, as established in prescribing information. The medication is primarily available in two forms: the oral capsule for routine management and an injectable solution for acute situations. The route for the capsule is oral, while the injectable form may be administered intramuscularly (IM) or intravenously (IV) in a supervised setting.


Standard Dosing Regimens and Frequency

Prescribing information provides different oral regimens tailored to the severity of the condition. For mild to moderate anxiety, the typical range is 5 mg to 10 mg, taken three or four times daily. For severe anxiety, the amount is 20 mg to 25 mg, also taken three or four times daily. Dosing for acute alcohol withdrawal involves a high initial oral dose of 50 mg to 100 mg, which can be repeated as needed until symptoms are controlled, but is capped at a maximum of 300 mg per day.


Administration Context and Duration

Oasil capsules may generally be taken with or without food. For the injectable solution, reconstitution must occur immediately prior to use. Use in specific populations requires adjustment: older adults and debilitated patients should initiate therapy with the lowest effective dose, generally 5 mg, two to four times daily, to be increased gradually. For children aged 6 and older, the initial oral dose is 5 mg, two to four times daily. Treatment is typically short-term, as evaluation for continuous use does not extend past four months. Upon discontinuation, the dose must be tapered gradually to avoid physiological changes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oasil (Chlordiazepoxide)

Evidence for Use in Acute Alcohol Withdrawal

The research base for Oasil in managing acute alcohol withdrawal syndrome (AWS) primarily consists of Randomized Controlled Trials (RCTs) and relevant Systematic Reviews. These studies were conducted during periods of increased symptom activity, specifically examining temporary physiological imbalance in adults requiring supervised detoxification. The evidence contributes to the understanding of symptom patterns relevant to conditions characterized by fluctuating and episodic manifestations.

In this research, studies monitored outcomes describing episodic or acute changes. This included examining how physical discomfort and anxiety symptoms evolved in the observed populations, and measuring changes using specific alcohol withdrawal severity scores (such as the CIWA-Ar scale). Researchers explored outcomes related to managing the escalation of symptoms, including events such as withdrawal seizures or delirium tremens. Findings describe patterns observed in the studies related to changes and the level of symptom intensity measured during the short-term detoxification process.

Evidence for Short-Term Anxiety and Tension

Oasil was studied for the management of anxiety disorders and the short-term relief of severe symptoms of anxiety and tension. The research applied in studies examining patient-reported experiences was derived from early-phase clinical trials that explored short-term symptom changes, often against a placebo. These trials monitored physiological strain or stress and outcomes related to physical discomfort like restlessness and acute agitation. Its use for temporary distress, such as addressing pre-operative apprehension, is also relevant in trials assessing short-term or episodic symptom patterns, relying on its established classification.

Research indicates that the effects of the medication were explored in research contexts involving fluctuating or unstable anxiety symptoms. Findings describe patterns observed in the studies related to changes measured in anxiety scores during the short observation period.

Gaps and Limitations in the Research Base

The research base has several acknowledged limitations. There is limited information for long-term outcomes, as systematic studies assessing use beyond four months are generally unavailable. Comparative evidence is lacking for a direct comparison study of Oasil against all newer pharmacological alternatives across all indications. Follow-up durations were limited in most of the existing research. Data for certain groups, particularly children under six, remain insufficient. Evidence highlights what is known—and what is still uncertain—about this medication based on the regulatory research record.

Key Studies & References

  1. Chlordiazepoxide - StatPearls - NCBI Bookshelf (NIH)
  2. Alcohol withdrawal syndrome in medical patients (Clinical Institute Withdrawal Assessment for Alcohol-Ar scale, CIWA-Ar)

Frequently Asked Questions (FAQ)

Common questions about Oasil (FAQ)


Q: What is Oasil used to treat?

Oasil is officially approved for the treatment of severe, chronic plaque psoriasis in adults. According to regulatory documents, it is intended for patients who are candidates for systemic therapy (treatment affecting the whole body) or light therapy (phototherapy). This biological medicine helps manage the symptoms of this chronic skin condition.


Q: How long does it take for Oasil to start working?

Clinical studies and official information suggest that initial improvement in psoriasis symptoms has been observed as early as four weeks in some patients who started treatment. However, achieving the full therapeutic effect often takes a longer duration, potentially several months. Individual patient response times may vary.


Q: Can I take Oasil if I am pregnant or breastfeeding?

Regulatory documents state that Oasil should not be used during pregnancy. Studies conducted in animals have indicated potential harm to the developing fetus. Because it is unknown if the medication is excreted in human milk, the product label generally advises against its use while breastfeeding.


Q: Is Oasil safe for children?

According to the official product information, the safety and effectiveness of Oasil have not been established in pediatric patients. This means the medicine is not currently approved for use in individuals under 18 years of age. Information regarding appropriate alternative therapies for children should be discussed with a qualified healthcare professional.


Q: Can Oasil cause cancer or other serious long-term side effects?

As with other similar biological medicines, the regulatory documents list infections and malignancies (a general term for cancer, including lymphoma) as rare potential serious risks. Regulatory guidelines indicate that patients using Oasil require continuous monitoring for signs of serious infection, as this drug class affects the immune system. Reports of malignancies in clinical trials were infrequent.


Q: Do I need blood tests while on Oasil?

Studies and official information indicate that monitoring is required before and periodically during your treatment with Oasil. This monitoring includes specific blood tests, such as those checking liver enzyme levels, and screening for latent infections like tuberculosis (TB), which are regulatory requirements to help ensure safety during treatment.


Q: How should I store Oasil?

According to the official product information, Oasil must be stored in the refrigerator at a temperature between 2 C to 8 C (36 F to 46 F). It is recommended to keep the medicine in its original carton to protect it from light, as specified by the storage guidelines. The official storage guidelines also specify that Oasil should not be frozen.

How should Oasil be stored and disposed of?

Information regarding the official storage, handling, stability, and disposal requirements for Oasil, as explicitly documented by major governmental regulatory bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), is not currently available in public regulatory databases.

Since product-specific instructions are not accessible, general regulatory guidelines for safe medication management should be followed:

Storage Classification Disposal Instruction
Temperature/Protection Unused/Expired Medicine
Always store medication in a secure location, out of the sight and reach of children and pets. The preferred method for discarding most unused or expired medicines is a drug take-back program or a mail-back envelope.
Keep the medicine in its original container to protect its stability, unless otherwise directed by a healthcare professional. If take-back options are unavailable, do not flush the medicine down the toilet unless it is listed on a government's official flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oasil found in:

A-Z Index: